Pharmafile Logo

Mayzent

- PMLiVE

New data puts Jakafi on course for blockbuster status

Novartis/Incyte drug meets targets in blood cancer trial

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

Novartis to close UK R&D site

Research operations at Horsham expected to end in June

Novartis day

Novartis commits to greater transparency on trials

Will provide anonymised patient-level data but only for new studies

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

Novartis day

Novartis under fire in Japan over Diovan promotion

Offices raided amid investigation into falsified data

Novartis building

Novartis skin cancer drug clears pivotal trial

Sonidegib achieves significant response in basal cell carcinoma patients

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

Biogen Idec building

EC approves Biogen’s oral MS drug Tecfidera

Will compete with Novartis' Gilenya and Sanofi's Aubagio

Novartis building

Novartis planning thousands more job cuts, says paper

NZZ am Sonntag claims pharma company plans to transfer roles to India

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links